Table. Recommendations for vaccination in people with asplenia or hyposplenia by age at the time of asplenia or hyposplenia diagnosis

• A complete age-appropriate course and booster doses of MenACWY vaccine are recommended. The number of doses depends on the vaccine brand and the person’s age when they start the vaccine course. See Table. Recommendations for MenACWY vaccine for people with a specified medical condition that increases their risk of invasive meningococcal disease.
• A complete age-appropriate course and booster doses of MenB vaccine are recommended. See Table. Recommendations for MenB vaccine for people with a specified medical condition that increases their risk of invasive meningococcal disease.

• 4 doses of PCV, with doses at 2, 4, 6 and 12 months of age. The dose at 6 months is an additional dose to the routine PCV schedule.
• A dose of PPV at 4 years of age
• A 2nd dose of PPV at least 5 years later

• 2 doses of MenACWY vaccine are recommended. See Table. Recommendations for MenACWY vaccine for people with a specified medical condition that increases their risk of invasive meningococcal disease.
• A complete age-appropriate course of MenB vaccine is recommended, with a single booster dose 3 years later. See Table. Recommendations for MenB vaccine for people with a specified medical condition that increases their risk of invasive meningococcal disease.

Children who have received a complete routine course of pneumococcal vaccination are recommended to receive the following additional doses:

• 1 dose of PCV at least 2 months after any previous doses of PCV
• 1 dose of PPV 2–12 months after the last dose of PCV from age 4 years
• A 2nd dose of PPV at least 5 years later

For children who have not received a full routine infant course of pneumococcal vaccination, see Table for the catch-up schedule for children with medical conditions associated with an increased risk of pneumococcal disease aged <5 years.

• 2 doses of MenACWY vaccine are recommended, with a booster dose at 3 or 5 years after the primary course (depending on age), and ongoing booster doses every 5 years after that. See Table. Recommendations for MenACWY vaccine for people with a specified medical condition that increases their risk of invasive meningococcal disease.
• A complete age-appropriate course of MenB vaccine is recommended, with a single booster dose 3 or 5 years after the primary course, depending on age. The number of doses depends on the vaccine brand. See Table. Recommendations for MenB vaccine for people with a specified medical condition that increases their risk of invasive meningococcal disease.

The following doses are recommended, regardless of previous vaccination:

• 1 dose of PCV
• 1 dose of PPV 2–12 months after the last dose of PCV
• A 2nd dose of PPV at least 5 years after the 1st dose of PPV
• If a person receives a dose of 21vPCV as their PCV dose, subsequent doses of 23vPPV are not required.

If the person has previously received a dose of PPV, the PCV dose should be given at least 12 months after the previous PPV dose. The 2nd dose of PPV should be given 12 months after the PCV dose or 5 years after the previous PPV dose, whichever is later.

Acronyms used: 

• Hib = Haemophilus influenzae type b 
• MenACWY = meningococcal ACWY
• MenB = meningococcal B 
• PCV = pneumococcal conjugate vaccine 
• PPV = pneumococcal polysaccharide vaccine

Footnotes:
^a Recommended but not funded under the National Immunisation Program